| Description | This product is a 51.3 kDa Human ADRB1 membrane protein expressed in HEK293. The protein is for research use only and is not approved for use in humans or in clinical diagnosis. | Recombinant Ebola Virus-like Particles (EBOV VLPs) are produced in mammalian HEK293 human cells, assembled with Nucleoprotein, Glycoprotein and Matrix protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material Recombinant Ebola Virus-like Particles (EBOV VLPs) are produced in mammalian HEK293 human cells, assembled with Nucleoprotein, Glycoprotein and Matrix protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. EBOV VLPs can be used in the development of EBOV diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More | This product GTTS-WQ7127MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research. | This product GTTS-WK5849MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the IL7R protein. This product can be used in -related researches. | Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. NoV GI.1 VLPs can be used in the development of NoV GI.1 diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More |